AN2 Therapeutics Completed Its 200-patient Observational Study In Acute Melioidosis. The Study Evaluated Patients Receiving The Current Standard Of Care: IV Meropenem Or Ceftazidime
Benzinga Newsdesk 1 year ago
BiotechNewsHealth CareGeneral
Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraboroleObservational Study funded by the National Institutes of Health
- Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraborole
- Observational Study funded by the National Institutes of Health